Summary: Hepatic drug transporters are responsible for both hepatic uptake and the biliary excretion of drugs. Expression changes in hepatic drug transporter genes have been observed in various pathophysiological conditions. However, it has not been comprehensively investigated what factors substantially influence the mRNA levels of hepatic drug transporters. In this study, we quantified the mRNA expression of 17 drug transporters using noncancerous liver tissue samples and carried out stepwise multiple regression analysis to identify the factors affecting their expression from 18 clinical variables. For 17 drug transporters, the mRNA level of organic anion transporting polypeptide (OATP) 2B1 was highest, followed by that of organic cation transporter 1, organic anion transporter 2, OATP1B1, OATP1B3, multidrug resistance-associated protein (MRP) 6, and MRP3. Stepwise multiple regression analysis demonstrated MRP4 mRNA level to be predicted with the greatest accuracy among 17 drug transporters. Of clinical variables entered into the prediction model for MRP4, hepatitis C virus (HCV) infection and liver cirrhosis were crucial factors affecting MRP4 mRNA and protein levels. Furthermore, HCV-related cirrhosis influenced the mRNA levels of 8 drug transporters besides MRP4. These findings indicate that HCV-related cirrhosis is a crucial factor affecting the expression of hepatic drug transporters, especially MRP4.
Introduction
Liver is a major organ for the detoxification of xenobiotics including drugs. Hepatic drug transporters, belonging to solute carriers (SLC) or ATP-binding cassette (ABC) transporters, are responsible for both the uptake of endogenous and exogenous compounds into hepatocytes and the biliary excretion of them or their metabolites. 1, 2) The former is mediated in part by SLC transporters, such as organic cation transporter (OCT) 1, 3) organic anion transporter (OAT) 2, 4) and organic anion transporting polypeptides (OATP1B1, OATP1B3, and OATP2B1), 5, 6) located at the sinusoidal membranes of hepatocytes, while the latter is mediated by canalicular ABC transporters, such as P-glycoprotein encoded by multidrug resistance (MDR) 1 gene, multidrug resistanceassociated protein (MRP) 2, and breast cancer resistance protein (BCRP), located at the canalicular membranes of hepatocytes. 7, 8) In addition, other members of the MRP family (e.g., MRP3 and MRP4) are expressed in the sinusoidal membranes of hepatocytes and involved in the efflux of their substrates into the blood. 9, 10) Accumulating evidence indicates that these transporters play crucial roles in the pharmacokinetics of clinically important drugs. Actually, a single nucleotide polymorphism (SNP), 521TÀC (Val174Ala) of OATP1B1, which reduces its transport activity, is associated with an increased plasma concentration of pravastatin, a cholesterol-lowering drug, 11) and increased risk of statin-induced myopathy. 12) Recent studies demonstrate that some polymorphisms of OCT1 are responsible for interindividual differences in the therapeutic efficacy and pharmacokinetics of metformin, an anti-diabetic drug. 13, 14) In addition, a loss of MRP2 function caused by mutations results in Dubin-Johnson syndrome, 15) a disease characterized by conjugated hyperbilirubinemia, suggesting that drug transporters are also involved in the homeostasis of endogenous substances.
Drug transporters are also expressed in the intestine and kidney, and contribute to the intestinal absorption and renal secretion of ionic drugs. 16, 17) We have demonstrated that mRNA levels of intestinal MDR1 and renal OAT3 regulate the pharmacokinetic properties of tacrolimus and cefazolin, respectively. [18] [19] [20] These results indicate that the expression levels as well as SNPs of drug transporters are responsible for individual variation in pharmacokinetics. Although data on the mRNA expression of drug transporters in the intestine and kidney have accumulated using human tissue samples, 21, 22) little is available on the expression profile of hepatic drug transporters.
Expression changes of many hepatic drug transporter genes have been observed in some pathophysiological conditions such as inflammation-induced icteric cholestasis, 23) primary biliary cirrhosis (PBC), 24) and obstructive cholestasis. 25) These studies examined whether interested one or two factors affect the expression of hepatic drug transporters. However, it has not been comprehensively investigated what factors substantially influence the mRNA levels of hepatic drug transporters, among various characteristics of patients. Therefore, in this study, the mRNA expression of 25 drug transporters, including the member of OCT, OAT, OATP, multidrug and toxin extrusion (MATE), peptide transporter (PEPT), MDR1, MRP, and BCRP, was quantified using noncancerous liver tissue samples from patients with liver tumors. Furthermore, we tried to identify the factors affecting the expression of hepatic drug transporters by conducting stepwise multiple regression analysis. Table 1 shows the patient characteristics. The samples were resected at the site most distant from the cancerous tissues, frozen in liquid nitrogen and stored at -809 C until RNA extraction and membrane preparation. This study was conducted in accordance with the Declaration of Helsinki and its amendments and approved by Kyoto University Graduate School and Faculty of Medicine, Ethics Committee. All patients gave their written informed consent.
Materials and Methods

Patients
Isolation of total RNA: Total cellular RNA was isolated from the samples using MagNA Pure LC RNA isolation Kit II (Roche Diagnostic GmbH, Mannheim, Germany) according to the manufacturer's instructions. The total RNA was reverse-transcribed, and the single stranded DNA was used for real-time PCR.
Quantification of hepatic drug transporter mRNA expression: The mRNA expression of hepatic drug transporters was quantified by real-time PCR using the ABI PRISM 7700 sequence detector (Applied Biosystems, Foster, CA) at least two times as described previously. 26) The primers and probes for OAT7, MRP1, MRP3-6, and BCRP were designed using the Primer Express software (Applied Biosystems) ( Table 2) . Those for others were described previously. 21, [26] [27] [28] As for OATP1B1, OATP1B3, OATP2B1, and MRP2, the mRNA expression levels measured in our previous study 29) were used.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was also quantified as an internal control with GAPDH control reagent (Applied Biosystems). Western blot analyses: Crude plasma membranes were prepared from the noncancerous liver tissues as described previously. 26) Crude plasma membrane fractions (50 mg) were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (NuPAGE 7% TrisAcetate gel; Invitrogen, Carlsbad, CA) and transferred onto polyvinylidene difluoride membranes (PVDF membrane 0.2 mm; Invitrogen) using an XCell II Blot Module (Invitrogen) according to the manufacturer's instructions. The blots were blocked with 1% non-fat dry milk in tris-buffered saline (TBS: 20 mM Tris, 137 mM NaCl, pH 7.5) containing 0.1% Tween 20 for MRP4 or 5% non-fat dry milk in TBS containing 0.3% Tween 20 for b-actin. The blots were then incubated overnight at 49 C with a primary antibody specific for MRP4 (M4I-10; Abcam, Cambridge, UK) (1:1000) or b-actin (AC-15; Sigma, St. Louis, MO) (1:2000). The bound antibody was detected on X-ray film by enhanced chemiluminescence with horseradish peroxidase-conjugated anti-rat or anti-mouse IgG antibody and cyclic diacylhydrazides (GE Healthcare Bio-Science Corp., Piscataway, NJ). b-actin was examined as an internal control. The relative amounts of the bands were determined densitometrically using ImageJ (National Institute of Health).
Statistical analysis: We carried out stepwise multiple regression analysis to evaluate the relation between the mRNA levels of hepatic drug transporters and 18 clinical variables using SPSS 11.0 (SPSS Japan Inc., Tokyo, Japan). In this analysis, mRNA levels of hepatic drug transporters and clinical variables were treated as dependent and independent variables, respectively. The 18 clinical variables were as follows: age, gender, hepatitis B virus infection, hepatitis C virus (HCV) infection, inflammatory activity (A), fibrosis staging (F), aspartate aminotransferase (AST), lactate dehydrogenase, alkaline phosphatase, albumin, total bilirubin, direct bilirubin (DBil), creatinine, creatine kinase (CK), C-reactive protein, Na ＋ , K ＋ , and Ca
2＋
. Based on the new Inuyama classification, inflammatory activity (A0, none; A1, mild; A2, moderate; A3, severe) and fibrosis staging (F0, no fibrosis; F1, fibrous portal expansion; F2, bridging fibrosis; F3, bridging fibrosis with architectural distortion; F4, cirrho- Fig. 1 . mRNA expression of 17 drug transporters (9 SLC and 8 ABC transporters) in the human liver Total cellular RNA was extracted from human noncancerous liver tissue, and reverse-transcribed. The mRNA levels were determined by real-time PCR using an ABI prism 7700 sequence detector. Each column represents the mean±S.D. for 105 patients. sis) were determined by the pathologist. The other 16 variables were divided into 2 or 3 groups based on reference ranges at Kyoto University Hospital, and all variables were changed to dummy variables. A value of pº0.05 was considered significant difference. The validity of this stepwise model was demonstrated because a backward model gave the same results. Comparisons between two groups were carried out using the MannWhitney U test. The correlation between groups divided based on the presence or absence of HCV infection and liver cirrhosis, and mRNA expression was analyzed using the Kruskal-Wallis test, followed by Dunn's test. These two statistical analyses were carried out with GraphPad PRISM version 4 (GraphPad Software, Inc., La Jolla, CA).
Results
Expression profile of hepatic drug transporters: First, GAPDH mRNA levels were measured as an internal control using total RNA from 117 subjects. The average value was 167.13±90.72 amol/mg of total RNA (mean±S.D.) and 12 subjects with GAPDH mRNA levels less than 1/20 of the mean were excluded from the study. Next, the mRNA expression of 17 SLC transporters (OCT1-3, OCTN1-2, OAT1-4, 7, OATP1B1, 1B3, 2B1, MATE1, 2-K, and PEPT1-2) and 8 ABC transporters (MDR1, MRP1-6, and BCRP) was quantified in 29 of 105 subjects. Overall, mRNA levels of SLC transporters were higher than those of ABC transporters. Eight SLC transporters whose mean mRNA levels were lower than 0.5 amol/mg RNA were not quantified in the remaining 76 subjects. These transporters are as follows: OCT2 (0.11 ±0.21 amol/mg RNA), OCT3 (0.22±0.12 amol/mg RNA), OCTN1 (0.06±0.04 amol/mg RNA), PEPT2 (0.02 ±0.02 amol/mg RNA), and OAT1, OAT3, OAT4, and MATE2-K (all less than 0.01 amol/mg RNA, mean±S.D., respectively). Figure 1 shows the mRNA levels of the remaining 17 drug transporters (9 SLC transporters and 8 ABC transporters) in 105 subjects. The expression profiles of these transporters in 105 subjects were analogous to those in 29 subjects. For SLC transporters, the mRNA level of OATP2B1 was highest (29.22±14.64 amol/mg RNA), followed by that of OCT1 (13.67±8.55 amol/mg RNA), OAT2 (11.63±7.05 amol/mg RNA), OATP1B1 (8.62±5.67 amol/mg RNA), OATP1B3 (3.12±2.65 amol/mg RNA), and MATE1 (2.41±1.73 amol/mg RNA). For ABC transporters, MDR1 (1.28±0.60 amol/mg RNA), MRP2 (2.37±1.60 amol/mg RNA), MRP3 (2.42± 1.24 amol/mg RNA), MRP6 (3.02±1.85 amol/mg RNA) showed strong expression, but their mRNA levels were lower than those of SLC transporters, especially OATP2B1, OCT1, and OAT2.
Stepwise multiple regression analysis: To comprehensively investigate the effects of various factors on the mRNA levels of hepatic drug transporters, stepwise multiple regression analysis was carried out using clinical variables available. Adjusted R square (R * 2 ), an index of the predictive accuracy of multiple regression models, and the clinical variables entered into the model are summarized in Table 3 . Multiple regression models predicting MRP4 mRNA levels showed the highest accuracy (R * 2 ＝0.509) among 17 hepatic drug transporters ( Table  3) . It is difficult to interpret all 17 models similarly, so we focused only on the MRP4 model in subsequent analyses. As shown in Table 4 , five clinical variables, that is, high D-Bil (À0.2 mg/dL), high K ＋ (À4.8 mEq/L), F4, low CK (male, Ã44 IU/L; female, Ã35 IU/L), and HCV (＋), are independent predictive factors for MRP4 mRNA expression.
Factors affecting MRP4 mRNA levels: Next, we investigated the effects of these five clinical variables on MRP4 mRNA levels individually using the Mann-Whitney U test. Based on the reference range at the Kyoto University Hospital, the patients were divided into two groups. As shown in Figure 2A -E, high D-Bil levels (3.16-fold, p ＝0.001), F4 (1.49-fold, p＝0.002), and HCV (＋) (1.87-fold, pº0.001) significantly increased MRP4 mRNA lev- els, but not low CK levels (p＝0.4083). The high K ＋ group was too small (n＝2) to carry out this statistical analysis. Although high D-Bil levels most influenced MRP4 mRNA expression, the high D-Bil group was also small (n＝5). On the other hand, there were appropriate numbers of F4 (n＝34) and HCV (＋) (n＝46) patients. These findings indicate that F4 and HCV (＋) rather than high D-Bil levels are crucial factors affecting MRP4 mRNA levels. Effects of HCV-related liver cirrhosis on mRNA and protein expression of MRP4: F4, which corresponds to liver cirrhosis, is closely related to HCV because liver cirrhosis is most commonly caused by hepatitis C. Therefore, we divided the patients into 4 groups based on the presence or absence of HCV infection and liver cirrhosis (F4). In the HCV-infected, liver cirrhosis group (n＝25), MRP4 mRNA levels increased by 2.06-fold compared with those in the non-infected, non-cirrhosis group (n＝50; Fig. 2F ), suggesting that combining these two information leads to improvement in the prediction of MRP4 mRNA expression. Furthermore, we investigated the effects of HCV-related cirrhosis on the MRP4 protein level. As shown in Figure 3 , the level also significantly increased in the HCV-infected, liver cirrhosis group (n＝4) compared to the non-infected, non-cirrhosis group (n＝4; 2.68-fold increase).
Effects of HCV infection and liver cirrhosis on mRNA expression of hepatic drug transporters: For the other 16 hepatic drug transporters, the influence of HCV infection or liver cirrhosis was investigated. The results are summarized in Table 5 . Unlike MRP4, the mRNA levels of many transporters, especially SLC transporters, significantly decreased in the HCV (＋) group or liver cirrhosis group. This tendency was more remarkable when the subjects were divided based on the presence of liver cirrhosis. Table 6 shows the influence of HCV-related cirrhosis on the mRNA expression of 17 hepatic drug transporters. In the HCV-infected, liver cirrhosis group, mRNA levels of several transporters (MATE1, 0.43-fold; MRP2, 0.49-fold; OATP1B3, 0.52-fold; OCT1, 0.53-fold; BCRP, 0.53-fold; OATP1B1, 0.56-fold increase) significantly decreased compared with those in the non-infected, non-cirrhosis group. On the other hand, mRNA levels of MRP1 (2.04-fold increase) and MDR1 (1.22-fold increase) significantly increased in the HCV-infected, liver cirrhosis group. The differences were significant only between the HCV-infected, liver cirrhosis group and non-infected, non-cirrhosis group.
Discussion
Hepatic drug transporters are responsible for the pharmacokinetics of various drugs. This is the first study to quantify the mRNA expression of SLC and ABC transporters in human liver tissue with large sample sizes (n＝ 105), although there are some reports with small sample sizes. 30, 31) Drug transporters such as OCT1, OATP1B1, and MRP2, reported to play crucial roles in hepatic clearance, 1, 2) also showed high mRNA levels, consistent with previous findings. The drug transporter whose mRNA level was highest in the liver was OATP2B1. OATP1B1 and OATP1B3, also members of the OATP family, have similar broad substrate specificity and are exclusively expressed in the liver. 5, 6) OATP2B1 has a much narrower specificity though its substrates overlap with those of OATP1B1 and OATP1B3. 5, 6) OATP2B1 is expressed in various tissues such as spleen, placenta, heart, and small intestine, as well as the liver. 5, 6) We recently identified a SNP (-282GÀA) in the OATP2B1 promoter region, which increases the mRNA expression of OATP2B1 in the liver. 29) Further studies are needed to elucidate the physiological and pharmacokinetic significance of the strong expression of OATP2B1 in the liver and identified SNP. MRP4 is an ATP-dependent efflux transporter for a variety of endogenous substrates and xenobiotics. Physiological substrates of MRP4 include cyclic nucleotides such as cAMP and cGMP, bile acids, eicosanoids, and conjugated steroid hormones. 9, 32) MRP4 is expressed in various tissues including the liver, 9) and is localized in the sinusoidal membranes of hepatocytes. 33) Recent studies demonstrate that MRP4 expression is induced in cholestatic patients 34) and animals with common bile duct ligation (CBDL). 35, 36) Furthermore, Mennone et al. 37) showed that CBDL Mrp4-null mice has more severe liver cell injury and lower serum bile acid levels than CBDL wild-type mice. These results suggest that MRP4 functions as an alternative basolateral bile acid efflux system in the adaptive response to cholestasis. In this study, we demonstrated that MRP4 mRNA and protein levels significantly increased in patients with HCV-related cirrhosis. Upregulation of MRP4 mRNA or protein expression in human liver has also been reported in cases of progressive familial intrahepatic cholestasis, 38) PBC, 39) and acetaminophen-induced acute liver failure. 40) Induction of MRP4 in patients with liver diseases including HCVrelated cirrhosis may serve to prevent further damage to hepatocytes through the increased efflux of potentially toxic compounds such as bile acids.
There have been several reports on the influence of HCV infection or fibrosis on the mRNA expression of hepatic drug transporters. Hinoshita et al. 41) demonstrated that MRP2 mRNA levels significantly decrease in HCV-infected liver tissue compared to non-HCV infected tissue. This finding is consistent with the present results. 
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On the other hand, Nakai et al. 42) reported remarkable decreases in mRNA levels of OCT1 and OATP1B1 according to fibrosis stage progression (F1 to F3) in chronic hepatitis C patients. In the present study, mRNA levels of some drug transporters including OCT1 and OATP1B1 significantly decreased in the patients with cirrhosis (F4) compared to non-cirrhosis patients (F0-F3) . In HCV-infected patients, mRNA levels of OCT1 and OATP1B1 tended to decrease according to fibrosis stage progression (F0 to F4), but the differences were not significant (data not shown). Differences in the population studied (Nakai et al. F0 and F4, F1 and F4, and F2 and F4 (data not shown) . Decreases in the expression of several SLC transporters including OCT1 and OATP1B1 may prevent the accumulation of endogenous and exogenous toxic compounds in damaged hepatocytes.
HCV infection is associated with elevated levels of reactive oxygen species (ROS) and decreased antioxidant levels in patients. 43) ROS production within hepatocytes leads to the activation of neighboring Kupffer cells and subsequent release of proinflammatory cytokines, such as tumor necrosis factor (TNF)-a. 43, 44) In primary human hepatocytes exposed to TNF-a, mRNA levels of some SLC transporters including OCT1, OATP1B1, and OATP1B3 decreased, 45) suggesting that TNF-a is in part responsible for the downregulation of SLC transporters in HCV-related cirrhosis. On the other hand, Burdette et al. 46) demonstrated that nuclear factor-E2-related factor 2 (Nrf2), which serves as a cellular sensor for oxidative stress, is activated in HCV-infected cells. Mrp4 induction under oxidative conditions is mediated via Nrf2 regulatory pathway. 47) The activation of Nrf2 regulatory pathway may be involved in MRP4 upregulation in HCV-related cirrhosis.
AST is a clinical variable entered into many multiple regression models for predicting mRNA levels of hepatic drug transporters. Serum AST levels are elevated in almost all cases of liver disease including viral hepatitis. Actually, in this study, serum AST levels significantly in- The fact that AST is entered into many multiple regression models may reflect the substantial influence of HCVrelated cirrhosis on the mRNA expression of hepatic drug transporters. Although high D-Bil levels most influenced MRP4 mRNA expression, all 5 patients with high D-Bil levels were infected with HCV, suggesting that the influence of high D-Bil on MRP4 expression is explained in part by HCV infection. On the other hand, low CK levels did not have significant effect on the MRP4 mRNA level as a whole, although multiple regression analysis demonstrated that low CK is one of the independent predictive factors for MRP4 mRNA expression level. The effects of low CK levels on the MRP4 mRNA level may be masked by other factors (e.g., HCV (＋) or F4). In this study, we did not take into consideration the presence of therapeutic agents or dietary factors. When these factors are added in independent variables, predictions for certain transporters may be improved.
In conclusion, we demonstrate in this study the expression profiles of 17 hepatic drug transporters in human liver tissue. Furthermore, HCV-related cirrhosis was identified as a factor affecting the expression of hepatic drug transporters in multivariate analysis. Table 5 . Effect of hepatitis C virus (HCV) infection and liver cirrhosis (LC) on mRNA expression of 17 hepatic drug transporters mRNA levels (amol/mg total RNA) Ratio mRNA levels (amol/mg total RNA) Ratio HCV, hepatitis C virus; LC, liver cirrhosis. Data are presented as mean±S.D. *pº 0.05, **pº 0.01, ***pº 0.001, significantly different from HCV (-), (LC) (-). HCV (-), LC (-), n＝50; HCV (＋), LC (-), n＝21; HCV (-), LC (＋), n＝9; and HCV (＋), LC (＋), n＝25.
